April 17, 2009 - GE Healthcare announced the company has signed a research agreement with Brigham and Women’s Hospital, an affiliate of Harvard Medical School, to establish an alliance in medical research in area of Positron Emission Tomography (PET).
The collaboration will leverage GE Healthcare’s Molecular Imaging (MI) research efforts to develop personalized approaches to the diagnosis and management of patients with oncologic, neurologic and cardiovascular diseases.
“Collaborations of this caliber are direct investments in the future of healthcare,” said Terri Bresenham, vice president of the GE Healthcare Molecular Imaging business. “Brigham and Women’s world-class patient care, in conjunction with their stellar research and clinical-trial track record, make them an optimal partner in discovering new MI technologies to diagnose and treat disease.”
Brigham and Women’s Hospital has consistently been a leader in the adoption of new medical imaging technologies and establishing their value in the clinic. Clinicians and scientists from both BWH and GE Healthcare plan to use the tools of molecular imaging and radiopharmaceutical development to further the cause of developing personalized approaches to the diagnosis and management of patients with oncologic, neurologic and cardiovascular diseases.
GE Healthcare’s Molecular Imaging division has 2,500 scientists at GE’s Global Research Centers with resources in chemistry, biology, drug development, engineering and imaging technology.
“The more we understand about disease from a clinical standpoint, the better equipped we are to build technologies to improve patient care,” said Jean-Luc Vanderheyden, GE Healthcare’s Global Molecular Imaging Leader. “This collaboration has the ability accelerate the process of developing more effective methods of diagnosing, treating and monitoring disease.”
For more information: www.gehealthcare.com
July 30, 2024 
